COVID-19 vaccines continue to be administered around the world every day, but a new one might be here to speed up the process.

Johnson & Johnson announced Friday their new "single-shot" vaccine has shown positive results, and they intend to file for U.S. Emergency Use Authorization in early February.

Editor's Choice: Health Care Workers Stuck In Snow Give COVID-19 Vaccine Doses To Stranded Drivers

These topline results with a single-shot COVID-19 vaccine candidate represent a promising moment. Paul Stoffels, M.D., Johnson & Johnson

The phase 3 trial of the vaccine posted what doctors are calling promising results, as it was 85% effective in preventing severe disease, and 66% effective overall in preventing moderate to severe COVID-19 across all regions studied.

The Pfizer and Moderna vaccines, both of which require two doses, showed over 90% effectiveness in preventing COVID-19, but Stoffels still calls the new vaccine's results "topline." 

"The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response," said Stoffels. 

Johnson & Johnson says the vaccine's safety profile matches others using the same technology, with 9% of volunteers developing a fever.

If approved by the FDA, 100 million doses could be ready by June, with doses of the vaccine starting to be administered as early as late February per ABC News.

Editor's Note: The CDC has a robust website with all the latest information on the vaccine and can answer any questions you may have. Click here for more information.